Anemia of Chronic Kidney Disease
Conditions
Brief summary
The aim of this study was to compare and evaluate efficacy and safety of intravenous CKD-11101 versus Darbepoetin alfa in patients who have renal anemia receiving hemodialysis.
Detailed description
This study was designed as randomized, double-blind, multi-center, Phase 3 clinical study to evaluate the efficacy and safety of intravenous CKD-11101 versus Darbepoetin alfa in patients who had renal anemia receiving hemodialysis. The selection criteria are evaluated for 19-year-old patients who receive stable hemodialysis treatment for 3 months or more in patients with chronic renal failure. After completion of the stabilization period of 12 to 16 weeks for Darbepoetin Alfa, the subjects with the mean Hb levels of 10 to 12g/dl measured during the baseline visit and 0 week visit are randomized to the test and control groups in a 1:1 ratio during the randomization visit. They have a 20-week maintenance period and a 4-week evaluation period.
Interventions
BIOLOGICALCKD-11101
BIOLOGICALNESP
Sponsors
Chong Kun Dang Pharmaceutical
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
Randomized, double-blind, multi-center, phase 3 clinical trial
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Inclusion Criteria 1. Patients with 19 years of age or older 2. Patients with anemia in chronic renal failure 3. Patients who started hemodialysis more than 3 months ago and receive appropriate hemodialysis, satisfying the following criterion: -Kt/V is ≥ 1.2 or Urea reduction ratio is ≥ 65% 4. Patients with the mean Hb levels of 10 to 12g/dl measured at the baseline and randomization visits 5. Patients with enough body iron stores who meet the following item: -Serum ferritin ≥ 100ng/ml or Transferrin saturation ≥ 20% 6. Patients who have provided written consent to participate in the trial voluntarily *
Exclusion criteria
1. Patients with uncontrolled hypertension 2. Patients who had hypersensitivity to erythropoietin agents 3. Patients who had known hypersensitivity to mammalian cell-derived products or diluting agents 4. Patients with history of severe cardiovascular diseases 5. Patients who have received red blood cell transfusion or hormone therapy for anemia correction within 12 weeks prior to randomization 6. Patients whose anemia is not caused by chronic renal failure or may affect anemia correction 7. Patients whose AST/ALT test results performed at screening exceed twice of normal upper limit 8. Patients who had experience of positive result in anti-erythropoietin antibody in previous treatment with erythropoiesis stimulating agent 9. Patients who have been planned to change the dialysis method
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changed amount of mean hemoglobin level in evaluation period compared to the baseline | ([Mean of hemoglobin level measured in Weeks 20 - 24] - [Mean of hemoglobin level measured at Weeks -4 - 0]) | The equivalence test on mean hemoglobin level of test drug and to Reference Drug administration groups in evaluation period (Weeks 20 - 24) compared to the baseline (Weeks -4 - 0) will be conducted. |
| Mean administration dose in evaluation period: Mean dose administered in Weeks 20 - 24 | Weeks 20 - 24 | The equivalence test on mean administration dose of test drug and to Reference Drug administration groups in evaluation period (Weeks 20 - 24) will be conducted. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Ratio of subjects who maintain hemoglobin level ≥ 10g/dl during maintenance period and evaluation period (interval of every 2 weeks) | Weeks 0 - 24 | Compare ratio of subjects who maintain hemoglobin level ≥ 10g/dl during maintenance period and evaluation period between groups (interval of every 2 weeks) |
| Ratio of subjects who changed dose during maintenance period and evaluation period | Weeks 0 - 24 | Ratio of subjects who changed dose: Compare ratio of subjects who change dose during maintenance period and evaluation period between groups |
| Ratio of subjects who achieve target level of hemoglobin during the evaluation period | Weeks 20 - 24 | Ratio of subjects who maintain target level of hemoglobin: Compare the number of subjects who do not deviate from target level of hemoglobin during the evaluation period between groups |
| Number of red blood cell transfusion per subject during maintenance period and evaluation period | Weeks 0 - 24 | Number of red blood cell transfusion per subject: Compare number of red blood cell transfusion per subject during maintenance period and evaluation period between groups |
| Ratio of subjects who receive transfusion during maintenance period and evaluation period | Weeks 0 - 24 | Ratio of subjects who receive red blood cell transfusion: Compare ratio of subjects who receive red blood cell transfusion during maintenance period and evaluation period between groups |
| Mean hemoglobin levels at Weeks 20 and 24 | Weeks 20, 24 | Mean hemoglobin level at Weeks 20 and 24: Compare mean hemoglobin level at Weeks 20 and 24 between groups |
Outcome results
None listed